Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection

被引:2
|
作者
Kumar, Neil R. [1 ]
Karanam, Veena C. [2 ]
Kumar, Shari [3 ]
Kumar, Sunil D. [4 ,5 ]
机构
[1] Univ Miami, Jackson Mem Hosp, Internal Med, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Miami, FL USA
[3] Columbia Univ, Coll Dent Med, New York, NY USA
[4] Broward Hlth Med Ctr, Pulm Crit Care, Ft Lauderdale, FL 33316 USA
[5] Broward Hlth Med Ctr, 1600 S Andrews Ave, Ft Lauderdale, FL 33316 USA
关键词
convalescent plasma; COVID-19; severe; late stage; life threatening;
D O I
10.14423/SMJ.0000000000001546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesCurrent evidence favors plasma to be effective against coronavirus disease 2019 (COVID-19) in critically ill patients in the early stages of infection. We investigated the safety and efficacy of convalescent plasma in specifically late-stage (designated as after 2 weeks of hospital admission) severe COVID-19 infection. We also conducted a literature review on the late-stage use of plasma in COVID-19.MethodsThis case series examined eight COVID-19 patients admitted to the intensive care unit (ICU) who met criteria for severe or life-threatening complications. Each patient received one dose (200 mL) of plasma. Clinical information was gathered in intervals of 1 day pretransfusion and 1 hour, 3 days, and 7 days posttransfusion. The primary outcome was effectiveness of plasma transfusion, measured by clinical improvement, laboratory parameters, and all-cause mortality.ResultsEight ICU patients received plasma late in the course of COVID-19 infection, on average at 16.13 days postadmission. On the day before transfusion, the averaged initial Sequential Organ Failure Assessment (SOFA) score, PaO2:FiO(2) ratio, Glasgow Coma Scale (GCS), and lymphocyte count were 6.5, 228.03, 8.63, and 1.19, respectively. Three days after plasma treatment, the group averages for the SOFA score (4.86), PaO2:FiO(2) ratio (302.73), GCS (9.29), and lymphocyte count (1.75) improved. Although the mean GCS improved to 10.14 by posttransfusion day 7, the other means marginally worsened with an SOFA score of 5.43, a PaO2:FiO(2) ratio of 280.44, and a lymphocyte count of 1.71. Clinical improvement was noted in six patients who were discharged from the ICU.ConclusionsThis case series provides evidence that convalescent plasma may be safe and effective in late-stage, severe COVID-19 infection. Results showed clinical improvement posttransfusion as well as decreased all-cause mortality in comparison to pretransfusion predicted mortality. Randomized controlled trials are needed to conclusively determine benefits, dosage, and timing of treatment.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 50 条
  • [21] Convalescent plasma therapy for patients with severe COVID-19: A case series study
    Huang, Jinbao
    Weng, Heng
    Lan, Changqing
    Li, Hongyan
    [J]. MEDICINE, 2022, 101 (31)
  • [22] The efficacy of convalescent plasma therapy in severe COVID-19 patients: a systematic review
    Muddasani, Swathi
    Kotlarsic, Zar
    Agadi, Kuchalambal
    Jeu, Michelle
    Chavarria, Amanda
    Edaki, Omoyeme
    Sanchez-Gonzalez, Marcos
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [23] Management of COVID-19 Virus Infection by Convalescent Plasma
    Cheraghali, Abdol Majid
    Abolghasemi, Hassan
    Eshghi, Peyman
    [J]. IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2020, 19 : 3 - 6
  • [24] SUCCESSFUL USE OF CONVALESCENT PLASMA FOR SEVERE COVID-19 INFECTION IN TWO ADOLESCENT PATIENTS
    Crosley, Caitlin
    Frayre, Philip
    Fenton, Kimberly
    Echeverri, Carolina
    Gaitan, Juliana
    Oliveira, Eduardo
    Ensor, Christopher
    Levent, Fatma
    [J]. CRITICAL CARE MEDICINE, 2021, 49 (01) : 85 - 85
  • [25] Convalescent plasma therapy: A passive therapy for an aggressive COVID-19
    Sahu, Kamal Kant
    Jindal, Vishal
    Siddiqui, Ahmad Daniyal
    Cerny, Jan
    Gerber, Jonathan M.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2251 - 2253
  • [26] COVID-19 convalescent plasma therapy and immuno deficiency
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    [J]. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2021, 28 (03) : 306 - 307
  • [27] Convalescent plasma therapy for Covid-19: A systematic review
    Seth, Tulika
    Elavarasi, Arunmozhimaran
    Sahoo, Ranjit Kumar
    Shalimar
    Madan, Karan
    Nischal, Neeraj
    Soneja, Manish
    Garg, Pramod
    Kameshwarprasad
    Sharma, Atul
    [J]. NATIONAL MEDICAL JOURNAL OF INDIA, 2020, 33 (04): : 213 - 221
  • [28] Risk mitigation for COVID-19 convalescent plasma therapy
    不详
    [J]. BIOPHARM INTERNATIONAL, 2021, 34 (02) : 25 - 25
  • [29] The Three Pillars of COVID-19 Convalescent Plasma Therapy
    Franchini, Massimo
    Liumbruno, Giancarlo Maria
    Piacentini, Giorgio
    Glingani, Claudia
    Zaffanello, Marco
    [J]. LIFE-BASEL, 2021, 11 (04):
  • [30] Convalescent plasma and hyperimmune globulin therapy in COVID-19
    Cagdas, Deniz
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (04) : 309 - 315